SummaryRMgm-66
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 15864297 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei NK65 |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | R. Rangarajan, A. Sultan, C. Doerig |
Name Group/Department | Department of Immunology and Infectious Diseases |
Name Institute | Harvard School of Public Health |
City | Boston |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-66 |
Principal name | clone b1, clone c2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Male and female gametocyte production is not affected. No exflagellation observed in mutant clone c2 and drastically reduced in mutant clone b1, therefore, a defect in male gamete formation. |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype See also the paper by Dorin-Semblat D. et al. (2007, Mol Microbiol 65, 1170-1180) for unsuccessful attempts to knock-out map2 in P. falciparum, indicating that in P. falciparum map2 has an essential function during sexual blood stage development. Additional information Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0933700 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1113900 | ||||||||||||||||||||||||
Gene product | mitogen-activated protein kinase 2 | ||||||||||||||||||||||||
Gene product: Alternative name | MAP2; MAP-2; MAPK2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid single cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | PstI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The mutant has been generated using a construct that integrates by single cross-over integration. The disadvantage of using such insertion constructs is that the construct can be removed from the genome, thereby restoring the wild type genotype. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |